Annamaria Ruzzo
Cited by
Cited by
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ...
European journal of cancer 44 (13), 1875-1882, 2008
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer
F Graziano, N Galluccio, P Lorenzini, A Ruzzo, E Canestrari, S D'Emidio, ...
J Clin Oncol 29 (36), 4789-4795, 2011
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ...
J Clin Oncol 24 (12), 1883-1891, 2006
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
F Graziano, A Ruzzo, F Loupakis, E Canestrari, D Santini, V Catalano, ...
Journal of Clinical Oncology 26 (9), 1427-1434, 2008
Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer
F Graziano, F Arduini, A Ruzzo, I Bearzi, B Humar, H More, R Silva, ...
Clinical Cancer Research 10 (8), 2784-2789, 2004
Genetic modulation of the let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan
F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ...
The pharmacogenomics journal 10 (5), 458-464, 2010
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A Ruzzo, F Graziano, F Loupakis, D Santini, V Catalano, R Bisonni, ...
The pharmacogenomics journal 8 (4), 278-288, 2008
Toll‐like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes
D Santini, S Angeletti, A Ruzzo, G Dicuonzo, S Galluzzo, B Vincenzi, ...
Clinical & Experimental Immunology 154 (3), 360-364, 2008
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer
B Humar, F Graziano, S Cascinu, V Catalano, AM Ruzzo, M Magnani, ...
Oncogene 21 (53), 8192-8195, 2002
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
GS Wong, J Zhou, JB Liu, Z Wu, X Xu, T Li, D Xu, SE Schumacher, ...
Nature medicine 24 (7), 968-977, 2018
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype
A Ruzzo, F Graziano, F Pizzagalli, D Santini, V Battistelli, S Panunzi, ...
Annals of oncology 16 (6), 887-892, 2005
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy
K Kawakami, F Graziano, G Watanabe, A Ruzzo, D Santini, V Catalano, ...
Clinical cancer research 11 (10), 3778-3783, 2005
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease
A Ruzzo, F Graziano, B Vincenzi, E Canestrari, G Perrone, N Galluccio, ...
The oncologist 17 (6), 823, 2012
Identification of seven novel germline mutations in the human E‐cadherin (CDH1) Gene
H More, B Humar, W Weber, R Ward, A Christian, C Lintott, F Graziano, ...
Human mutation 28 (2), 203-203, 2007
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at‐risk Italian population
F Graziano, K Kawakami, A Ruzzo, G Watanabe, D Santini, F Pizzagalli, ...
International journal of cancer 118 (3), 628-632, 2006
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment withá…
F Graziano, F Arduini, A Ruzzo, A Mandolesi, I Bearzi, R Silva, P Muretto, ...
Annals of oncology 15 (3), 489-492, 2004
The system can't perform the operation now. Try again later.
Articles 1–20